Impax Laboratories, Inc. (NASDAQ: IPXL) confirmed that the U.S. Food and Drug Administration (FDA) has granted final approval of the Company’s Abbreviated New Drug Application (ANDA) for generic version of Depakote® (divalproex ER) 250mg Extended-release Tablets. The Company also received tentative approval on the 500mg tablets and expects to receive final approval on August 3, 2009, upon expiration of the 180-day exclusivity period. Abbott Laboratories markets Depakote® ER for the treatment of epilepsy and bipolar disorders.

The Company expects to launch both the 250mg and 500mg tablets on August 3, 2009, through Global Pharmaceuticals, Impax’s generic division.

According to Wolters Kluwer Health, U.S. sales of Depakote® ER 250mg and 500mg tablets were approximately $115 million and $796 million, respectively, for the 12 months ended March 2009.

Source
Impax Laboratories, Inc.

• Long-Term Tolerability And Safety Data Of Abilify(R) In Combination Treatment For Patients With Bipolar I Disorder
• Schizophrenia-Linked Gene Controls The Birth Of New Neurons
• Patients With Bipolar Disorder Have Higher Specialty Care Costs Than Patients With Diabetes And Other Chronic Diseases
• ">
• FDA Advisory Committee Votes In Favor Of Zyprexa For Two Adolescent Indications
• Schering-Plough Submits Response To FDA For SAPHRIS(TM) (asenapine) In The Acute Treatment Of Both Schizophrenia And Bipolar I Disorder
• Bipolar Disorder - Eurand Announces FDA Approval Of EUR-1048 (Lamictal(R) ODT(TM)), Co-Developed With GlaxoSmithKline

No Comments »

No comments yet.

RSS feed for comments on this post. TrackBack URL

Leave a comment

You must be logged in to post a comment.